Program Disclosure. This activity is supported by an educational grant from Intercept Pharmaceuticals.
|
|
- Jonah Briggs
- 6 years ago
- Views:
Transcription
1
2 Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of Purdue University College of Pharmacy and the Chronic Liver Disease Foundation. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians. This activity is supported by an educational grant from Intercept Pharmaceuticals.
3 Educational Objectives Examine current and emerging data relating to the diagnosis of PBC. Develop evidence-based treatment plans for patients with PBC using the latest clinical evidence. Identify disease-related symptoms and long-term medical management strategies to improve patient quality of life.
4 CLDF National Primary Biliary Cholangitis (PBC) Coalition The Chronic Liver Disease Foundation (CLDF) is pleased to invite you to become a member of a nationwide coalition of certified providers designed to improve the screening and treatment of patients with Primary Biliary Cholangitis (PBC). It is critically important that community specialists understand the importance of screening, diagnosis and appropriate management of PBC, as well as locating qualified specialists for PBC Linkage to Care. Upon completing CLDF curriculum delivered via this live meeting, an online module or an e-monograph, healthcare providers will receive a certificate of competency and will be offered enrollment into the CLDF National PBC Coalition.
5 Your Role If interested in becoming a member, please opt in on the form provided in your meeting folder. Your name will be included in the Resource Directory on the ACG Coalition website. Additional benefits include: Patient Registry Participation Market Research Phase IV Opportunities Latest Data on PBC Community Speaker Bureau Patient Advocacy and Outreach via Town Hall Meetings
6 Primary Biliary Cholangitis (PBC)
7 PBC is a Chronic, Progressive Autoimmune Disease Factors possibly associated with onset and perpetuation of bile-duct injury in PBC Genetics Immune response Bile duct damage Environment PBC is characterized by destruction of the interlobular and septal bile ducts that may lead to cirrhosis Poupon R. J Hepatol. 2010;52(5): ; Selmi C, et al. Lancet. 2011;377(9777): ; Carey EJ, et al. Lancet. 2015;386(10003):
8 PBC Phenotype Age Usually >45 years Gender Serology Immunoglobulin Female > Male (9:1) AMA in ~95%; disease-specific ANA in ~30%-50%; ASMA may be present IgM typically elevated MRCP Liver Histology Coexisting IBD Normal Lymphocytic infiltrate; inflammatory duct lesion; granuloma may be present Not typical Abbreviations: AMA, antimitochondrial antibody; ANA, antinuclear antibody; ASMA, anti-smooth-muscle antibody; IBD, inflammatory bowel disease; MRCP, magnetic resonance cholangiography; PBC, primary biliary cholangitis. Trivedi PJ, et al. Aliment Pharmacol Ther. 2012;36:
9 PBC Prevalence Boonstra K, Kunst A, Stadhouders P, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-base study. Liver International. 2014;34:e35.
10 Concomitant Autoimmune Disease in Women with PBC Frequency (%) Sjögren s syndrome 7-34 Raynaud s syndrome 9-13 Hashimoto s thyroiditis Rheumatoid arthritis 3-8 Psoriasis 6 Scleroderma or CREST* 1-2 Inflammatory bowel disease 1 Any autoimmune disease *CREST (calcinosis, Raynaud s phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia) Carey EJ, Ali AH, Lindor KD. Primary Biliary Cirrhosis. The Lancet Oct.; 386(10003):
11 Diagnostic Considerations Spectrum of Autoimmune Liver Injuries 1 Autoimmune hepatitis 1 Primary biliary cholangitis 1 Primary sclerosing cholangitis 1 IgG4-related disease 2 Differential for Cholestatic Liver Biochemistry 3 Drug-induced liver injury Inherited cholestasis Idiopathic ductopenia Malignant infiltration Nonalcoholic fatty liver disease Biliary obstruction Primary biliary cholangitis Primary sclerosing cholangitis Sarcoidosis 1. Trivedi PJ, et al. Aliment Pharmacol Ther. 2012;36: ; 2. Joshi D, et al. Aliment Pharmacol Ther. 2014;40: ; 3. Hirschfield GM, et al. Best Pract Res Clin Gastroenterol. 2011;25:
12 Diagnosis of PBC: Is Biopsy Needed? If: Increased AMA ALP >1.5 x ULN AST <5 x ULN Then: Positive predictive value for PBC >98% Sensitivity 80%, specificity 92% Abbreviations: ALP, alkaline phosphatase; AST, aspartate aminotransferase; ULN, upper limit of normal Zein CO, Angulo P, Lindor K. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?; Clin Gastro and Hepatol 2003;1(2):89-95.
13 Evaluation of Patients with Cholestatic Profile + PBC* AMA ANA + ** Specific PBC Nonspecific Ultrasound; immunoglobulins; medications; thyroid; celiac screen; lipids; bone density; Sjögren s screen *** MRCP +/- liver biopsy if MRCP nondiagnostic *0.5% 1% of healthy individuals are AMA+; **>85% patients with AMA PBC are ANA+; ***Differential is among PSC, antibody- negative PBC, and alternate ductopenic disorders. Abbreviations: AMA, antimitochondrial antibody; ANA, antinuclear antibody; MRCP, magnetic resonance cholangiography; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis. Hirschfield GM, et al. Best Pract Res Clin Gastroenterol. 2011;25:
14 Interpretation of AMA, ANA, and Immunoglobulin Testing in PBC AMA ANA Positive in >90% of patients with PBC, depending on assay 1 In the correct context, AMA reactivity, with an elevated ALP and no significant elevation in AST, is associated with a >95% PPV of histologic PBC 2 2 ANA immunofluorescent patterns are specific to PBC: multiple nuclear dots and perinuclear/rim-like membranous 3 gp210 and sp100 Automated ANA assays will likely not detect these reactivities Laboratories should perform immunofluorescence if ELISA-based assays for gp210 and sp100 are not available Immunoglobulins Elevated IgM is a sensitive but not specific characteristic of PBC 1 Elevated IgG is primarily observed in AIH 1 Abbreviations: PPV, positive predictive value; AIH, autoimmune hepatitis; IgM, immunoglobin M; IgG, immunoglobin G 1. Trivedi PJ, et al. Aliment Pharmacol Ther. 2012;36: ; 2. Zein CO, et al. Clin Gastroenterol Hepatol. 2003;1:89-95; 3. Zeman MV, Hirschfield GM. Can J Gastroenterol. 2010;24:
15 Overlap or Crossover Scenarios Immunoserologic Overlap Positive ANA/ASMA titers and elevated IgG in AMApositive PBC AMA-positive AIH Radiologic Overlap Clinical features of AIH with cholangiographic abnormalities consistent with inflammatory cholangiopathy Biochemical Overlap AST/ALT >5 x ULN in PBC or PSC ALP >3 x ULN in AIH (GGT >5 x ULN in children) Histologic Overlap Lymphoplasmacytic infiltrate and interface hepatitis with bile-duct lesions consistent with either PBC or PSC Also, varying combinations of the above, including temporal variations: consecutive vs sequential presentations Abbreviation: GGT, gamma-glutamyl transferase Trivedi PJ, et al. Aliment Pharmacol Ther. 2012;36:
16 Survival Rates, Elastography and PBC Abbreviation: LSM, liver stiffness measurement Corpechot C, Carrat F, Poujol-Robert A, et al. Hepatology. 2012; 56(1):
17 Higher APRI is Associated with Poorer Transplant-Free/Overall Survival in PBC Abbreviation: APRI, aspartate aminotransferase/platelet ratio. Trivedi PJ, Bruns T, Cheung A, et al. Optimizing risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. J Hepatol. 2014;60(6):
18 Disease Management
19 Pruritus Is Common Among PBC Patients Prevalence reported as high as 69% 1 Unknown etiology 1,2 Bile salts, endogenous opioids, histamine, serotonin, progesterone/ estrogen, and autotaxin/lysophosphatidic acid are suspected pruritogens 2 Diurnal variation most intense itch in the late evening 2 Localization reported at limbs soles of feet, palms of hands 2 Exacerbated by pregnancy or contact with wool/heat 3 1. Imam MH, et al. J Gastroenterol Hepatol. 2012;27(7): ; 2. Beuers U, et al. Hepatology. 2014;60(1): ; 3. Lindor KD, et al. Hepatology. 2009;50(1):
20 Stepwise Approach to Pruritus Cholestyramine (4-16 g/day) Anion exchange resin Difficult posology Bloating, constipation or diarrhea, nausea Rifampin ( mg/day) PXR agonist, lowers autotaxin 10% risk of hepatitis usually occurring in the first 2 months Naltrexone (12.5 to 50 mg/day) Opioid antagonist Loss of appetite, irritability, GI side effects Sertraline ( mg/day) SSRI Somnolence, nausea, dizziness, fatigue Abbreviations: SSRI, selective serotonin reuptake inhibitor; PXR pregnane X receptor, AASLD and EASL guidelines 2009.
21 Assessing and Managing Fatigue Though fatigue caused by PBC may not be reversible, associated causes of fatigue should be actively excluded or identified and managed 1,2 Rule Out: Associated causes of fatigue (disease or medication): Anemia 2 Depression 2 Sleep disorder 2 Hypothyroidism 1-3 Medications that can cause or contribute to fatigue (eg, excessive antihypertensive medication) 1 Consider Fatigue Management Strategies: Fatigue may be improved by: Maintaining regular physical activity 4,5 Modafinil ( mg) 6,7 Methotrexate for patients with severe fatigue 8 1. European Association for the Study of the Liver. J Hepatol. 2009;51(2): ; 2. Lindor KD, et al. Hepatology. 2009;50(1): ; 3. Elta GH, et al. Dig Dis Sci. 1983;28(11): ; 4. Cook NF, et al. Br J Nurs. 1997;6(14): ; 5. Graydon JE, et al. Cancer Nurs. 1995;18(1):23-28; 6. Jones DEJ, et al. Aliment Pharmacol Ther. 2007;25(4): ; 7. Ian Gan S, et al. Dig Dis Sci. 2009;54(10): ; 8. Babatin MA, et al. Aliment Pharmacol Ther. 2006;24(5):
22 The Absence of Symptoms at Diagnosis May Not Predict Prognosis Examination of the natural history of a 770-patient cohort in Northeast England (incident cases, ) % asymptomatic at diagnosis Median survival time from diagnosis was not significantly different between patients who were symptomatic and asymptomatic at diagnosis 1 The relationship between symptom severity and disease progression can vary by patient 2 Proportion Surviving Initially asymptomatic patients Initially symptomatic patients P = Time from Diagnosis (Yr) No. at risk Prince MI, et al. Gut. 2004;53: ; 2. Lindor KD, et al. Hepatology. 2009;50:
23 PBC Approved Therapies
24 First Line: Ursodeoxycholic Acid/Ursodiol (UDCA) Orally administered, naturally occurring, hydrophilic secondary bile acid Dose: mg/kg/day Improvement in liver tests may be seen within a few weeks and 90% of the improvement usually occurs within 6-9 months After 1 year of treatment, the number of patients with biochemical response according to Paris Criteria was 66% and according to Barcelona Criteria was 62% (Kuiper et al) Up to 40% treated with UDCA have a suboptimal response Abbreviation: UDSA, ursodeoxycholic acid Kuiper, et al. Gastroenterology 2009; 136(4):
25 Therapeutic Effects: UDCA Improves TB, ALP, GGT, AST and ALT Improves survival free of liver transplantation UDCA mg/kg/day Improves cholesterol, IgM Delays development of esophageal varices Delays histological progression Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; IgM, immunoglobulin M; TB, total bilirubin; UDCA, ursodeoxycholic acid. Levy C and Lindor KD. In: Zakim and Boyer's Hepatology: A Textbook of Liver Disease. Elsevier Inc;2011: Graphic courtesy of Dr. Cynthia Levy.
26 UDCA: Transplant-free Survival Based on Bilirubin and Alkaline Phosphatase Levels at 1 Year Follow-up Transplant-free survival (%) a-b: P.001 c-d: P.001 a b c d Normal bilirubin and ALP 2.0 x ULN Normal bilirubin and ALP > 2.0 x ULN Abnormal bilirubin and ALP 2.0 x ULN Abnormal bilirubin and ALP > 2.0 x ULN Time (years) a b c d Lammers, et al. Gastroenterology. 2014; 147:
27 GLOBE Score to Predict Outcomes of PBC Patients Receiving UDCA International collaborative meta-analysis >4000 patients with PBC from 15 centers in 8 European and North American countries On UDCA for at least 1 year Median follow-up 7.8 years Risk score developed and validated to predict transplant-free survival Lammers WJ, et al. Gastroenterology. 2015;149:
28 GLOBE Score: Online Calculation ALP at 1 year Total Bilirubin at 1 year Albumin at 1 year Age at initiation of UDCA GLOBE Platelets at 1 year Predicts 3-, 5- and 10-year survival compared to age-matched population
29 Second Line: Obeticholic Acid (OCA) FXR Agonist Bile Acid Homeostasis Inflammation Pathways Decreases BA synthesis Decreases BA uptake Decreases BA absorption Increases BA secretion Downregulates NF-KB, TNF Decreases IgM and CRP CHOLERESIS Abbreviations: BA, bile acid; NF-KB, nuclear factor kappa beta; TNF, tumor necrosis factor; CRP, C-reactive protein
30 Screening OCA in Patients with PBC: POISE Study Design Placebo (n=73) OCA 10 mg (n=73) OCA 5 mg OCA 5-10 mg dose adjustment option OCA 5 mg Titrate to OCA 10 mg (n=33) Remain at OCA 5 mg (n=36) Months in Open-Label Phase 0 W2 M3 M6 M9 M12 OCA titration at 6 months: Subjects in OCA titration arm titrated from 5 mg to 10 mg at Month 6 if they met any of the following criteria at the Month 6 assessment: The primary endpoint (ALP < 1.67xULN or bilirubin ULN) was not achieved No evidence of tolerability issues, e.g. pruritus Modified from Nevens F et al. N Engl J Med 2016;375:
31 Primary Objective and Patient Population To assess the proportion of patients achieving ALP <1.67 x ULN and a decrease of 15% and total bilirubin ULN Inclusion PBC diagnosis (EASL and AASLD guidelines) ALP 1.67 x ULN and/or total bilirubin >ULN to <2 x ULN Stable UDCA or unable to tolerate UDCA Exclusion Concomitant liver diseases, decompensation, severe pruritus requiring treatment Randomization Strata UDCA (yes/no) Paris 1: ALP >3x ULN and/or AST >2x ULN and/or total bilirubin >ULN Nevens F et al. N Engl J Med. 2016;375:
32 Patients with Response (%) Primary Endpoint in the Double-blind and Open-label Extension Phases Placebo Obeticholic acid, 5-10 mg Obeticholic acid,10 mg 100 Double-Blind Phase Open-Label Phase 5 mg Dose adjustment Month in Double-Blind Phase Month in Open-Label Phase No. of Patients Placebo Obeticholic acid, 5-10 mg Obeticholic acid, 10 mg Nevens F, et al. N Engl J Med. 2016;375:
33 Alkaline Phosphatase (U/liter) Alkaline Phosphatase in the Double-blind and Open-label Phases Placebo Obeticholic acid, 5-10 mg Obeticholic acid, 10 mg A Alkaline Phosphatase Double-Blind Phase Open-Label Phase mg Dose adjustment x ULN 100 ULN 0 Baseline Month in Double-Blind Phase Month in Open-Label Phase No. of Patients Placebo Obeticholic acid, 5-10 mg Obeticholic acid, 10 mg Nevens F, et al. N Engl J Med. 2016;375:
34 Totla Bilirubin (mg/dl) Total Bilirubin During the Double-blind and Open-label Phases B Total Bilirubin 1.4 Double-Blind Phase Open-Label Phase 5 mg Dose adjustment ULN Baseline Month in Double-Blind Phase Month in Open-Label Phase Nevens F, et al. N Engl J Med. 2016;375:
35 Findings on Obeticholic Acid in PBC: POISE Obeticholic acid is associated with statistically significant, clinically meaningful improvements 1 Biochemical criteria correlated with clinical benefit (alkaline phosphatase and bilirubin) Markers of inflammation (C-reactive protein) and apoptosis (CK18) Efficacy and safety of obeticholic acid Demonstrated when analyzed according to disease severity/response criteria 2 Consistent across patient subgroups 3 Age at diagnosis Disease duration Baseline alkaline phosphatase levels Abbreviation: PBC, primary biliary cirrhosis. 1. Nevens F, et al. Hepatology. 2014;60(suppl):347A-348A; 2. Luketic VA, et al. Hepatology. 2014;60(suppl):355A-356A; 3. Andreone P, et al. Hepatology. 2014;60(suppl):360A.
36 Adverse Events in POISE and Open-Label Extension Event Placebo N=73 n (%) OCA 5-10 mg N=70 n (%) OCA 10 mg N=73 n (%) Open Label N=193 n (%) Pruritus 28 (38) 39 (56) 50 (68) 138 (72) Nasopharyngitis 13 (18) 17 (24) 13 (18) 45 (23) Headache 13 (18) 12 (17) 6 (8) 36 (19) Fatigue 10 (14) 11 (16) 17 (23) 50 (26) Nausea 9 (12) 4 (6) 8 (11) 28 (15) Serious Adverse Events 3 (4) 11 (16) 8 (11) 27 (14) Modified from Nevens F, et al. N Engl J Med. 2016;375:
37 LS Mean (SE) Change from Baseline in Pruritus VAS Score Changes in Pruritus Over Time Double Blind Phase 30 Placebo ± UDCA (N=73) Obeticholic acid, 5-10 mg ± UDCA (N=70) Obeticholic acid, 10 mg ± UDCA (N=73) *** 20 ** * Month Abbreviations: VAS, visual analog scale; LS, least squares Nevens F, et al. N Engl J Med. 2016;375:
38 Overall Findings The effect of OCA was consistent and independent of age at diagnosis, duration of PBC and baseline ALP. Titration from 5 to 10 mg based on clinical response improved tolerance, minimized dropouts due to pruritus, and showed comparable efficacy to 10 mg OCA after 1 year. Thus, starting patients on OCA 5 mg with titration to 10 mg based on the clinical response appears to be an appropriate dosing strategy. OCA given to individuals with PBC with an inadequate response to, or unable to tolerate UDCA, produced a significant clinically meaningful improvement in liver biochemistry, which has been shown to correlate strongly with clinical benefit. Changes in noninvasive measures of liver fibrosis did not differ significantly between either treatment group and the placebo group at 12 months. Nevens F, et al. N Engl J Med. 2016;375:
39 Summary PBC is most common in middle-aged women Taking a good history is essential Diagnosis can typically be made based on persistent cholestatic liver profile and AMA positivity after other common liver diseases have been excluded
40 Long-term Management of Patients with PBC Liver tests every 3-6 months consider OCA if non response to UDCA Thyroid status (TSH) annually DEXA at baseline and every 2-4 years Monitor for associated autoimmune conditions In the presence of severe cholestasis assess levels of vitamins A and D. May need to administer Vit K prior to procedures Upper endoscopy every 1-3 years if cirrhotic or Mayo risk score >4.1 Ultrasound ± AFP every 6 months in patients with known or suspected cirrhosis Abbreviations: TSH, thyroid stimulating hormone; DEXA, dual energy X-ray absorptiometry; AFP, alpha fetoprotein Lindor K, et al. Hepatology 2009;50: ; EASL clinical guidelines. J Hepatology 2009; Japanese guidelines Hepatology Research 2014.
Diagnosis and Management of PBC
Diagnosis and Management of PBC Cynthia Levy, MD, FAASLD University of Miami Miller School of Medicine Miami, Florida 1 Primary Biliary Cholangitis (PBC) Chronic cholestatic liver disease Autoimmune in
More informationNew insights in pathogenesis and therapy of primary biliary cholangitis. Keith D. Lindor Dean Professor of Medicine
New insights in pathogenesis and therapy of primary biliary cholangitis Keith D. Lindor Dean Professor of Medicine OUTLINE PBC Epidemiology Diagnosis Treatment Incidence of PBC and PSC Trends Boonstra
More informationLiver Disease That Presents with Jaundice (PBC, Alcohol and Drugs): Diagnosis and Patient Management. Emma Pham, PA-C
Liver Disease That Presents with Jaundice (PBC, Alcohol and Drugs): Diagnosis and Patient Management Emma Pham, PA-C Case: JL (jaundiced lady) A 72 year old woman presents to her primary care provider
More informationOcaliva (obeticholic acid tablets)
Ocaliva (obeticholic acid tablets) Policy Number: 5.01.619 Last Review: 11/2018 Origination: 11/2016 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationRisk stratification in PBC
Risk stratification in PBC Christophe Corpechot Reference Center for Inflammatory Biliary Diseases Saint-Antoine hospital, Paris, France What is currently known (background) PBC : chronic, progressive
More informationCurrent Concepts in the Management and Treatment of PBC & PSC
Current Concepts in the Management and Treatment of PBC & PSC Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London A family affair? Central vein Hepatocytes
More informationPBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?
22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical
More informationHangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam
Clinical Aspects of Primary Biliary Cirrhosis Hangzhou, 15 March 2008 Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Epidemiology of Primary
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis PBC Foundation (UK) Ltd 6 Hill Street Edinburgh EH2 3JZ Tel: +44 (0) 131 556 6811 info@pbcfoundation.org.uk www.pbcfoundation.org.uk PBC for Healthcare Practitioners Introduction
More informationPrimary Biliary Cirrhosis : NOT ANY MORE!! PRIMARY BILIARY CHOLANGITIS
Primary Biliary Cirrhosis : NOT ANY MORE!! PRIMARY BILIARY CHOLANGITIS Nikolaos T. Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD Associate Professor and Chief, Division of Gastroenterology and Hepatology
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ocaliva (obeticholic acid) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ocaliva (obeticholic acid) Prime Therapeutics will review Prior Authorization
More informationOverview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN
Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN 2012 Annual Conference PSC Partners Seeking a Cure May 5, 2012 Primary Sclerosing Cholangitis Multifocal
More informationHépatopathies auto-immunes
16 ème Journée d'automne Lausanne, le 19 octobre 2017 Hépatopathies auto-immunes Nurullah Aslan et Darius Moradpour Service de Gastroentérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationChronic Cholestatic Liver Diseases
Chronic Cholestatic Liver Diseases - EASL Clinical Practice Guidelines - Rome, 8 October 2010 Ulrich Beuers Department of Gastroenterology and Hepatology Tytgat Institute of Liver and Intestinal Research
More informationTABLE OF CONTENTS SYMPOSIUM AGENDA. Diagnosis, Stratification of Risk, and Initial Treatment in PBC
PBC Novel Pathways for Treatment of Cholestatic Liver Disease TABLE OF CONTENTS Faculty Biographies SYMPOSIUM AGENDA Introduction Kris V. Kowdley, MD Diagnosis, Stratification of Risk, and Initial Treatment
More informationACG Clinical Guideline: Primary Sclerosing Cholangitis
ACG Clinical Guideline: Primary Sclerosing Cholangitis Keith D. Lindor, MD, FACG 1, Kris V. Kowdley, MD, FACG 2, and M. Edwyn Harrison, MD 3 1 College of Health Solutions, Arizona State University, Phoenix,
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationPBC treatment: the present and future. Maggie Bassendine Professor of Hepatology
PBC treatment: the present and future Maggie Bassendine Professor of Hepatology Primary biliary cirrhosis 20-25yrs OLT/ Death Symptoms: Fatigue, itching, jaundice Autoimmune disease: Focal small bile duct
More informationObeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks
Obeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks Draft Background and Scope Background: April 21, 2016 Primary biliary cholangitis
More informationSarah Landes October 23, 2014
Sarah Landes October 23, 2014 A T-cell mediated inflammatory destruction of intralobular bile ducts progressively leading to cholestasis and cirrhosis 9:1 F to M ratio Mostly diagnosed between 30-60 years
More informationPrimary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants
Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic
More informationMorning Report Presentation. Sarah Hughes, MD January 11, 2005
Morning Report Presentation Sarah Hughes, MD January 11, 2005 Primary Biliary Cirrhosis! PBC is a chronic, progressive, cholestatic liver disease of unknown cause that usually affects middle-aged women
More informationKa-Shing Cheung, MBBS, MPH 1, Wai-Kay Seto, MD 1,2, James Fung, MD 1,2, Ching-Lung Lai, MD 1,2 and Man-Fung Yuen, MD, PhD 1,2
Citation: (2017) 8, e100; doi:10.1038/ctg.2017.23 Official journal of the American College of Gastroenterology www.nature.com/ctg Prognostic Factors for Transplant-Free Survival and Validation of Prognostic
More informationAESOP Overview and Inclusion/Exclusion Criteria Richard Pencek, PhD
747-207 AESOP Overview and Inclusion/ Criteria Richard Pencek, PhD Sr Director, Clinical Research, Intercept Pharmaceuticals, Inc. 2 PSC Forum 2 AESOP: A Phase 2 Randomized, Placebo-Controlled Trial, Dose-Finding
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis What is primary biliary cholangitis? Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic liver disease. When a person has PBC, the immune
More informationNoncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis
Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids Cholestasis Biochemical hallmark Impaired bile flow from liver to small intestine Alkaline phosphatase is primary
More informationPediatric PSC A children s tale
Pediatric PSC A children s tale September 8 th PSC Partners seeking a cure Tamir Miloh Assistant Professor Pediatric Hepatology Mount Sinai Hospital, NY Incidence Primary Sclerosing Cholangitis (PSC) ;
More informationShifting Paradigms in Primary Biliary Cholangitis A CE/CME Activity
Overview Shifting Paradigms in Primary Biliary Cholangitis A CE/CME Activity In this video series, Kris Kowdley, MD, and Seth Sclair, MD, share insight into changes in the management of patients with primary
More informationI have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES
LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate
More informationPrimary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study
LINDOR ET AL. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases Keith D. Lindor 1, Christopher L. Bowlus 2, James Boyer 3, Cynthia Levy 4,
More informationPBC features and management in the era of UDCA and Budesonide
PBC features and management in the era of UDCA and Budesonide Raoul Poupon, MD Université P&M Curie, AP-Hôpitaux de Paris, Inserm, Paris, France The changing pattern of PBC Over the last 2 decades: More
More informationPrimary biliary cholangitis
A guide to Primary biliary cholangitis Miss Jennifer Hayden, Autoimmune Liver Disease Clinical Nurse Specialist Professor Gideon M Hirschfield, Professor and Consultant Transplant Hepatologist Centre for
More informationImproving the Lives of Patients with Liver Diseases
Improving the Lives of Patients with Liver Diseases Corporate Presentation March 2019 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties and
More informationBiliary tract diseases of the liver
Biliary tract diseases of the liver Digestive Diseases Course Bucharest 2016 Rob Goldin r.goldin@imperial.ac.uk How important are biliary tract diseases? Hepatology 2011 53(5):1608-17 Approximately 16%
More informationAutoimmune Liver Diseases
2nd Pannonia Congress of pathology Hepato-biliary pathology Autoimmune Liver Diseases Vera Ferlan Marolt Institute of pathology, Medical faculty, University of Ljubljana Slovenia Siofok, Hungary, May 2012
More informationAutoimmune and cholestatic liver diseases
Autoimmune and cholestatic liver diseases Prof. Tom Hemming Karlsen Research Institute of Internal Medicine & Department of Transplantation Medicine University of Oslo & Oslo University Hospital, Norway
More informationPrimary Sclerosing Cholangitis Medical Management
Primary Sclerosing Cholangitis Medical Management Kapil Chopra M.D. Assistant Professor of Medicine Division of Transplant Medicine Mayo Clinic Arizona PSC Primary sclerosing cholangitis is a progressive
More informationCASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationSingle Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785
Single Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785 Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment
More informationPrognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark
Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very
More informationA Review of Liver Function Tests. James Gray Gastroenterology Vancouver
A Review of Liver Function Tests James Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationSubject: Obeticholic Acid (Ocaliva ) Tablet
09-J2000-65 Original Effective Date: 09/15/16 Reviewed: 07/11/18 Revised: 08/15/18 Subject: Obeticholic Acid (Ocaliva ) Tablet THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationKey Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto
Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective Jenny Heathcote, MD University of Toronto Key Points: AILD comprise autoimmune hepatitis, primary biliary cirrhosis
More informationFat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
More informationIdiopathic adulthood ductopenia manifesting as jaundice in a young male
Idiopathic adulthood ductopenia manifesting as jaundice in a young male Deepak Jain*,1, H. K. Aggarwal 1, Avinash Rao 1, Shaveta Dahiya 1, Promil Jain 2 1 Department of Medicine, Pt. B.D. Sharma University
More informationChronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths
Chronic Biliary Disease Dr Susan Davies & Dr Bill Griffiths Chronic Biliary Disease Terminology is confusing with pathologists and hepatologists using the same language BUT with different meanings. Chronic
More informationPRIMARY BILIARY CHOLANGITIS: DIAGNOSIS AND MANAGEMENT Project ID:
ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint
More informationHepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
More informationPediatric Primary Sclerosing Cholangitis and Potential Therapies
Pediatric Primary Sclerosing Cholangitis and Potential Therapies Philip Rosenthal, M.D. Professor of Pediatrics & Surgery University of California, San Francisco DISCLOSURE I have the following financial
More informationIn primary biliary cholangitis (PBC), progression
HEPATOLOGY COMMUNICATIONS, VOL. 2, NO. 6, 2018 Clinical Application of the GLOBE and United Kingdom-Primary Biliary Cholangitis Risk Scores in a Trial Cohort of Patients With Primary Biliary Cholangitis
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationLIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA
LIVER SPECIALTY CONFERENCE USCAP 2016 Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA Nothing to disclose Case History 47-year-old male, long standing ileal
More informationTREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)
TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC) URSO not indicated Therapy for PBC Difficulties Etiology is uncertain Therapies are based on ideas regarding pathogenesis Present medical therapies have a limited
More informationTowards Precision Medicine in Primary Biliary Cholangitis
Riunione Monotematica A.I.S.F. 2016 THE FUTURE OF LIVER DISEASES: Beyond HCV is there a role for the hepatologist? 14 th October 2016 Towards Precision Medicine in Primary Biliary Cholangitis Marco Carbone,
More informationHow the concept of biochemical response influenced the management of primary biliary cholangitis over time
ORIGINAL ARTICLE How the concept of biochemical response influenced the management of primary biliary cholangitis over time W.J. Lammers 1 *, M. Leeman 1, C.I.J. Ponsioen 2, K. Boonstra 2, K.J. van Erpecum
More informationPatologia sistematica V Gastroenterologia Prof. Stefano Fiorucci Autoimmune liver diseases
Patologia sistematica V Gastroenterologia Prof. Stefano Fiorucci Autoimmune liver diseases Harrison s Principles of Internal Medicine 18-19 Ed. 2012 e seguenti Chronic hepatitis classification by cause
More informationACCME/Disclosures. PBC and PSC Revisited 4/6/2016. Primary Biliary Cirrhosis Cholangitis (PBC)
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationDiagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful?
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:935 940 Diagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful? REGAN L. EBBESON* and RICHARD
More informationColangitis Esclerosante Primaria: Manejo Clínico y Endoscópico
Colangitis Esclerosante Primaria: Manejo Clínico y Endoscópico Andrés Cárdenas, MD, MMSc, PhD, AGAF, FAASLD GI / Liver Unit, Hospital Clinic Institut de Malalties Digestives i Metaboliques Associate Professor
More informationOverview of PSC Making the Diagnosis
Overview of PSC Making the Diagnosis Tamar Taddei, MD Assistant Professor of Medicine Yale University School of Medicine Overview Definition Epidemiology Diagnosis Modes of presentation Associated diseases
More informationNot All Patients With Liver Disease Have HCV Diagnosis and Management of Some Common Non HCV Liver Diseases
Not All Patients With Liver Disease Have HCV Diagnosis and Management of Some Common Non HCV Liver Diseases Prevalence of Chronic Liver Disorders in the United States Nonalcoholic Fatty Liver Disorder
More informationCholestatic Liver Diseases: Update on Diagnosis and Management. Cholestatic Liver Diseases: Location of Injury Determines Phenotype
Cholestatic Liver Diseases: Update on Diagnosis and Management R. Todd Stravitz, M.D. Hume-Lee Transplant Center Section of Hepatology Virginia Commonwealth University Cholestatic Liver Diseases: Location
More informationTratamiento endoscópico de la CEP. En quien como y cuando?
Tratamiento endoscópico de la CEP. En quien como y cuando? Andrés Cárdenas, MD, MMSc, PhD, AGAF, FAASLD GI / Liver Unit, Hospital Clinic Institut de Malalties Digestives i Metaboliques University of Barcelona
More informationPBC and PSC: Back to Basics
Disclosure No financial interest or other relationship with the manufacturer(s) of the product(s) or provider(s) of the service(s) that will be discussed in this presentation. PBC and PSC: Back to Basics
More informationTwo Cases of Primary Sclerosing Cholangitis Overlapping with Autoimmune Hepatitis in Adults
CASE REPORT Two Cases of Primary Sclerosing Cholangitis Overlapping with Autoimmune Hepatitis in Adults Go Igarashi 1, Tetsu Endo 1, Kenichiro Mikami 1, Naoya Sawada 1,RyuSatake 1, Rie Ohta 1, Juichi Sakamoto
More informationEfficacy and Safety of Seladelpar in Primary Biliary Cholangitis 52-Week Analysis of a Dose-Ranging Phase 2 Study
Efficacy and Safety of Seladelpar in Primary Biliary Cholangitis 52-Week Analysis of a Dose-Ranging Phase 2 Study Bowlus CL, Neff G, Aspinall R, Galambos M, Goel A, Hirschfield G, Kremer AE, Mayo MJ, Swain
More informationFatty Liver Disease A growing epidemic
Fatty Liver Disease A growing epidemic Updates in GIM for Primary Care Don C. Rockey March 9 th, 2018 Disclosures 2018 Research Funding (all to MUSC) NIH/NIDDK Actelion Pharmaceuticals Gilead Sciences
More informationIn 1993, the International Autoimmune Hepatitis Group
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:417 421 Validation and Modification of Simplified Diagnostic Criteria for Autoimmune Hepatitis in Children ELIZABETH MILETI,* PHILIP ROSENTHAL,*, and MARION
More informationPrimary biliary cirrhosis (PBC) is an autoimmune
Early Biochemical Response to Ursodeoxycholic Acid and Long-Term Prognosis of Primary Biliary Cirrhosis: Results of a 14-Year Cohort Study Li-Na Zhang, 1,2 * Tian-Yan Shi, 1,2 * Xu-Hua Shi, 1,2 Li Wang,
More informationNoninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD
Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis
More informationObeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks
Obeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks Evidence Report July 26, 2016 Institute for Clinical and Economic
More informationManagement of cholestatic diseases Today and tomorrow
12th Paris Hepatology Conference Management of cholestatic diseases Today and tomorrow Paris 15 January 2019 U. Beuers Department of Gastroenterology & Hepatology Tytgat Institute for Liver and Intestinal
More informationPresentation and mortality of primary biliary cirrhosis in older patients
Age and Ageing 2000; 29: 305 309 Presentation and mortality of primary biliary cirrhosis in older patients JULIA L. NEWTON 1,DAVID E. JONES 2,JANE V. METCALF 2,JAY B. PARK 2,ALISTAIR D. BURT 2, MARGARET
More informationPrimary biliary cholangitis (PBC)
The PBC Network Primary biliary cholangitis (PBC) Living with your diagnosis Officially endorsed and reviewed by About this guide The European Association for the Study of the Liver (EASL) is a major European
More informationApproach to the Patient with Liver Disease
Approach to the Patient with Liver Disease Diagnosis of liver disease Careful history taking Physical examination Laboratory tests Radiologic examination and imaging studies Liver biopsy Liver diseases
More informationNonalcoholic Fatty Liver Disease in Children: Typical and Atypical
Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion
More informationHEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM
EVALUATION OF LIVER FUNCTION R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty HEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM METABOLIC FUNCTION
More informationHepatic Transporter Proteins involved in Bile Formation
Bile salt synthesis Hepatic Transporter Proteins involved in Bile Formation Basolateral membrane transporter proteins fx: NTCP uptake of bile salts OATP bulky organic anions Canalicular membrane transporter
More informationUpdate on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic
Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics
More informationNON-ALCOHOLIC FATTY LIVER DISEASE:
NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology
More informationWEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry
MPharm Programme Liver Biochemistry Slide 1 of 49 MPHM Liver Biochemistry Learning Outcomes Assess and evaluate the signs and symptoms of illness Assess and critically appraise a patients medication regimen,
More information21/07/2017. Update on Autoimmune Biliary Disease. Changing Role of Liver Biopsy in PBC and PSC. Primary Biliary Cirrhosis Cholangitis
Primary Biliary Cirrhosis Cholangitis Update on Autoimmune Biliary Disease Changing Change in Nomenclature for PBC : From Cirrhosis to Cholangitis (EASL Panel, Beuers et al J Hepatol Nov 2015, Gut Nov
More informationTHE BRITISH SOCIETY OF GASTROENTEROLOGY/UK-PBC PRIMARY BILIARY CHOLANGITIS TREATMENT AND MANAGEMENT GUIDELINES
THE BRITISH SOCIETY OF GASTROENTEROLOGY/UK-PBC PRIMARY BILIARY CHOLANGITIS TREATMENT AND MANAGEMENT GUIDELINES AUTHORS: HIRSCHFIELD GM, DYSON JK, ALEXANDER GJ, CHAPMAN M, COLLIER J, HUBSCHER S, PATANWALA
More informationSerologic Markers CONVENTIONAL ANTIBODIES ANTIBODIES UNCONVENTIONAL. AIH Type I
Autoimmune Hepatitis By Thomas Frazier Objective What we need to know about AIH Diagnosis Treatment Difficulties in both Liver transplantation concerns AASLD Guidelines: Hepatology. 2010 Jun;51(6):2193-213.
More informationValue of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1355 1360 Value of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease PIOTR MILKIEWICZ,*, HAYMAN BUWANESWARAN,* CATALINA
More informationHwajeong Lee, MD, Robert T. Stapp, DO, Adrian H. Ormsby, MD, and Veena V. Shah, MD
Anatomic Pathology / Overlap Syndrome The Usefulness of IgG and IgM Immunostaining of Periportal Inflammatory Cells (Plasma Cells and Lymphocytes) for the Distinction of Autoimmune Hepatitis and Primary
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationLaboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland
Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland Sanjiv Chopra, MD, MACP Professor of Medicine Harvard Medical School Editor In Chief Hepatology Section Up To Date Serum
More informationWELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here.
WELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here. Photograph of an actual patient What is OCALIVA? OCALIVA is a prescription medicine used to
More informationBiomarkers of PSC. Steve Helmke, Ph.D.
Biomarkers of PSC Steve Helmke, Ph.D. steve.helmke@ucdenver.edu Biomarkers of PSC Currently Used in Clinical Practice Biomarkers Used in Prognostic Models of PSC Wiesner et al, 1989 Age Bilirubin Biopsy
More informationAutoimmune hepatitis
Autoimmune hepatitis: Autoimmune hepatitis a spectrum within a spectrum Alastair Burt Professor of Pathology and Dean of Clinical Medicine Newcastle University Spectrum of autoimmune liver disease Autoimmune
More informationHigh dose UDCA in the Treatment of Primary Sclerosing Cholangitis. Falk Meeting,Freiberg2006 Dr RW Chapman John Radcliffe Hospital Oxford,UK
High dose UDCA in the Treatment of Primary Sclerosing Cholangitis Falk Meeting,Freiberg2006 Dr RW Chapman John Radcliffe Hospital Oxford,UK Specific Medical Therapy for PSC Immunosuppressants -prednisolone
More informationA Retrospective Single-Center Review of Primary Sclerosing Cholangitis in Children
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:239 245 A Retrospective Single-Center Review of Primary Sclerosing Cholangitis in Children TAMIR MILOH,* RONEN ARNON,* BENJAMIN SHNEIDER, FREDERICK SUCHY,*
More informationACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries Paul Y. Kwo, MD, FACG, FAASLD 1, Stanley M. Cohen, MD, FACG, FAASLD 2, and Joseph K. Lim, MD, FACG, FAASLD 3 1 Division of Gastroenterology/Hepatology,
More informationMY DISCUSSION GUIDE. Personalize your treatment plan for primary biliary cholangitis (PBC).
I am not on OCALIVA (obeticholic acid) MY DISCUSSION GUIDE Personalize your treatment plan for primary biliary cholangitis (PBC). This guide is not intended to replace the advice of your healthcare team.
More informationInterface hepatitis in PBC: Prognostic marker and therapeutic target
Interface hepatitis in PBC: Prognostic marker and therapeutic target Raoul Poupon Service d Hépatologie, Hôpital Saint-Antoine, Paris Faculté de Médecine Pierre & Marie Curie, Paris Key features of
More informationUpdate on Autoimmune Liver Disease. Role of Liver Biopsy in Autoimmune Hepatitis, PBC and PSC
Update on Autoimmune Liver Disease Role of Liver Biopsy in Autoimmune Hepatitis, PBC and PSC Stefan Hübscher, School of Cancer Sciences, University of Birmingham Dept of Cellular Pathology, Queen Elizabeth
More informationDrug-induced liver injury
Drug-induced liver injury Vincent Wong MBChB(Hons), MD, FRCP, FHKCP, FHKAM Professor, Department of Medicine and Therapeutics Director, Cheng Suen Man Shook Foundation Centre for Hepatitis Studies Deputy
More information